SCHEMBL5452293

SCHEMBL5452293

CCCCc1ccc(-c2ccc(C3(O)CCN(C(=O)OCC(=O)NC)CC3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.50
OPRL1 P41146 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.38
RARB P10826 3/20 0.38
PLK1 P53350 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
CHRM4 P08173 1/20 0.37
HPGD P15428 2/20 0.37
ALDH1A1 P00352 1/20 0.37
DRD2 P14416 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
HTR1A P08908 1/20 0.35
DRD1 P21728 1/20 0.35
DRD5 P21918 1/20 0.35
SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5445764 0.85 FAAH (0.45) FAAHOPRL1L3MBTL1OPRM1OPRD1
SCHEMBL5442739 0.84 FAAH (0.57) FAAHOPRL1OPRM1ALDH1A1DRD2
SCHEMBL5453462 0.84 SMN1; SMN2 (0.46) FAAHDRD2SMN1; SMN2DRD3CCR1
SCHEMBL5452097 0.83 GAA (0.46) FAAHL3MBTL1ALDH1A1SMN1; SMN2HRH1
SCHEMBL5447927 0.83 SMN1; SMN2 (0.45) FAAHOPRL1OPRM1OPRD1OPRK1
SCHEMBL5447955 0.81 FAAH (0.44) FAAHOPRL1OPRM1OPRD1OPRK1
SCHEMBL5443508 0.80 FAAH (0.46) FAAHL3MBTL1OPRM1CHRM4ALDH1A1
SCHEMBL5442748 0.80 FAAH (0.47) FAAHOPRL1L3MBTL1OPRM1OPRD1
SCHEMBL1581807 0.80 OPRL1 (0.58) OPRL1RARBOPRM1OPRD1OPRK1
SCHEMBL5445830 0.78 FAAH (0.46) FAAHOPRM1ALDH1A1DRD2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021405-A1 ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021405-A1 ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, HRH2 FAAH 1/4885OPRL1 375/4885L3MBTL1 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.